1.Davis, S, Tappenden, P, Cantrell, A. A review of studies examining the relationship between progression-free survival and overall survival in advanced or metastatic cancer. London: National Institute for Health and Care Excellence (NICE), 2012.
2.Latimer, NR. Survival analysis for economic evaluations alongside clinical trials: Extrapolation with patient-level data. Med Decis Making. 2013;33:743-754.
3.Latimer, NR, Abrams, KR, Lambert, PC, et al. Adjusting survival time estimates to account for treatment switching in randomized controlled trials: An economic evaluation context. Med Decis Making. 2014;34:387-402.
4.Ciani, O, Davis, S, Tappenden, P, et al. Validation of surrogate endpoints in advanced solid tumors: Systematic review of statistical methods, results, and implications for policy makers. Int J Technol Assess Health Care. 2014;30:312-324.
5.Imai, H, Mori, K, Ono, A, et al. Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. Med Oncol. 2014;31:1-7.
6.Imai, H, Mori, K, Wakuda, K, et al. Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. Ann Thorac Med. 2015;10:61-66.
7.Kasahara, N, Imai, H, Kaira, K, et al. Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy. Radiol Oncol. 2015;49:409-415.
8.Yoshino, R, Imai, H, Mori, K, et al. Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. Mol Clin Oncol. 2014;2:731-736.
9.Yoshino, R, Imai, H, Mori, K, et al. Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer. J Cancer Res Ther. 2015;11:606.
10.Shitara, K, Matsuo, K, Muro, K, Doi, T, Ohtsu, A. Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy. J Cancer Res Clin Oncol. 2013;139:1383138-9.
11.Aboshi, M, Kaneko, M, Narukawa, M. Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2014;140:839-848.
12.Bria, E, Massari, F, Maines, F, et al. Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma: Correlation with overall survival, benchmarking and power analysis. Crit Rev Oncol Hematol. 2015;93:50-59.
13.Delea, TE, Khuu, A, Heng, DY, Haas, T, Soulieres, D. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. Br J Cancer. 2012;107:1059-1068.
14.Li, X, Liu, S, Gu, H, Wang, D. Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib. J Cancer Res Clin Oncol. 2012;138:1963-1969.
15.Shitara, K, Ikeda, J, Yokota, T, et al. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: Analysis of 36 randomized trials. Invest New Drugs. 2012;30:1224-1231.
16.Félix, J, Aragão, F, Almeida, JM, et al. Time-dependent endpoints as predictors of overall survival in multiple myeloma. BMC Cancer. 2013;13:1-12.
17.Giessen, C, Laubender, RP, Ankerst, DP, et al. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: Literature-based analysis from 50 randomized first-line trials. Clin Cancer Res. 2013;19:225-235.
18.Han, K, Ren, M, Wick, W, et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: A literature-based meta-analysis from 91 trials. Neuro Oncol. 2013;16:696-706.
19.Petrelli, F, Barni, S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol. 2013;24:186-192.
20.Petrelli, F, Barni, S. Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials. Transl Lung Cancer Res. 2013;2:6-13.
21.Sidhu, R, Rong, A, Dahlberg, S. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials. Clin Cancer Res. 2013;19:969-976.
22.Beauchemin, C, Cooper, D, Lapierre, M-È, Yelle, L, Lachaine, J. Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer. Onco Targets Ther. 2014;7:1101-10.
23.Flaherty, KT, Hennig, M, Lee, SJ, et al. Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trials. Lancet Oncol. 2014;15:297-304.
24.Singh, S, Wang, X, Law, C. Association between time to disease progression end points and overall survival in patients with neuroendocrine tumors. Gastrointest Cancer. 2014;4:103-113.
25.Cartier, S, Zhang, B, Rosen, VM, et al. Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: A systematic review and meta-analysis of published clinical trial data. Oncol Res Treat. 2015;38:88-94.
26.Chen, Y-P, Sun, Y, Chen, L, et al. Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials. Radiother Oncol. 2015;116:157-166.
27.Giessen, C, Laubender, RP, Ankerst, DP, et al. Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials. Acta Oncol. 2015;54:187-193.
28.Petrelli, F, Coinu, A, Borgonovo, K, Cabiddu, M, Barni, S. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: Meta-analysis of 30 randomized first-line trials. Hepatobiliary Pancreat Dis Int. 2015;14:124-131.
29.Amir, E, Seruga, B, Kwong, R, Tannock, IF, Ocaña, A. Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer? Eur J Cancer. 2012;48:385-388.
30.Hotta, K, Suzuki, E, Di Maio, M, et al. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer. 2013;79:20-26.
31.Kawakami, H, Okamoto, I, Hayashi, H, et al. Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. Eur J Cancer. 2013;49:3003-3009.
32.Petrelli, F, Barni, S. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: An analysis of the first-line phase III trials. Med Oncol. 2014;31:1-8.
33.Adunlin, G, Cyrus, JWW, Dranitsaris, G. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: A trial-level meta-analysis. Breast Cancer Res Treat. 2015;154:591-608.
34.Hotta, K, Kato, Y, Leighl, N, et al. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: Systematic review. PLoS One. 2015;10:e0121211.
35.Johnson, KR, Liauw, W, Lassere, MND. Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: A systematic review. Ann Oncol. 2015;26:485-496.
36.Özer-Stillman, I, Strand, L, Chang, J, Mohamed, AF, Tranbarger-Freier, KE. Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor. Clin Cancer Res. 2015;21:295-302.
37.Suzuki, H, Hirashima, T, Okamoto, N, et al. Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure. Asia Pac J Clin Oncol. 2015;11:121-128.
38.Moriwaki, T, Yamamoto, Y, Gosho, M, et al. Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: A meta-analysis of randomised trials of first-line chemotherapy. Br J Cancer. 2016;114:881-888.
39.Petrelli, F, Barni, S. Surrogate end points and postprogression survival in renal cell carcinoma: An analysis of first-line trials with targeted therapies. Clin Genitourin Cancer. 2013;11:385-389.
40.Shitara, K, Matsuo, K, Muro, K, Doi, T, Ohtsu, A. Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer. 2014;17:362-370.
41.Ciani, O, Buyse, M, Garside, R, Peters, J, Saad, ED, Stein, K, et al. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. J Clin Epidemiol. 2015;68:833-842.
42.Terashima, T, Yamashita, T, Takata, N, et al. Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. Hepatol Res. 2015;46:650-656.
43.Galsky, MD, Krege, S, Lin, CC, et al. Relationship between 6-and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. Cancer. 2013;119:3020-3026.
44.Halabi, S, Rini, B, Escudier, B, Stadler, WM, Small, EJ. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer. 2014;120:52-60.
45.Négrier, S, Bushmakin, AG, Cappelleri, JC, et al. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer. 2014;50:1766-1771.
46.Laporte, S, Squifflet, P, Baroux, N, et al. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: Evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open. 2013;3:e001802.
47.Mauguen, A, Pignon, J-P, Burdett, S, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients' data. Lancet Oncol. 2013;14:619-26.
48.Agarwal, N, Bellmunt, J, Maughan, BL, et al. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer. 2014;12:130-137.
49.Foster, NR, Renfro, LA, Schild, SE, et al. Multitrial evaluation of progression-free survival as a surrogate end point for overall survival in first-line extensive-stage small-cell lung cancer. J Thorac Oncol. 2015;10:1099-1106.
50.Shi, Q, De Gramont, A, Grothey, A, et al. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database. J Clin Oncol. 2015;33:22-28.
51.Paoletti, X, Oba, K, Bang, Y-J, et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: A meta-analysis. J Natl Cancer Inst. 2013;105:1667-70.
52.Michiels, S, Pugliano, L, Marguet, S, et al. Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol. 2016;27:1029-1034.
53.IQWiG. Validity of surrogate endpoints in oncology: Executive summary of rapid rep–rt A10-05, Version 1.1. Institute for Quality and Efficiency in Health Care: Executive Summaries. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2005.
54.Lencioni, R, Llovet, JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
55.Burzykowski, T, Buyse, M, Piccart-Gebhart, MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26:1987-1992.
56.Kim, C, Prasad, V. Strength of validation for surrogate end points used in the US Food and Drug Administration's approval of oncology drugs. Mayo Clin Proc. 2016;91:713-725.
57.Prentice, RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med. 1989;8:431-440.
58.Ciani, O, Buyse, M, Drummond, M, et al. Use of surrogate end points in healthcare policy: A proposal for adoption of a validation framework. Nat Rev Drug Discov. 2016;15:516.
59.Buyse, M, Molenberghs, G, Burzykowski, T, Renard, D, Geys, H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1:49-67.
60.Stevens, W, Philipson, T, Wu, Y, Chen, C, Lakdawalla, D. A cost-benefit analysis of using evidence of effectiveness in terms of progression free survival in making reimbursement decisions on new cancer therapies. Forum Health Econ Policy. 2014;17:21-52.
61.Saad, ED, Katz, A. Progression-free survival and time to progression as primary end points in advanced breast cancer: Often used, sometimes loosely defined. Ann Oncol. 2008;20:460-464.
62.Kemp, R, Prasad, V. Surrogate endpoints in oncology: When are they acceptable for regulatory and clinical decisions, and are they currently overused?. BMC Med. 2017;15:134.